# Tirzepatide Hitting Weight, Blood Pressure and Cholesterol Targets at Once

How often tirzepatide participants reached three study thresholds together, and why SURMOUNT-4’s placebo group is reported separately.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/tirzepatide-three-targets-at-once
Updated: 2026-11-15
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# Tirzepatide Hitting Weight, Blood Pressure and Cholesterol Targets at Once

A post hoc SURMOUNT analysis found that 22–34% of tirzepatide participants met weight, blood pressure and cholesterol thresholds together at the 15% weight-loss cutoff.

Editorial profile: [Wesley Jenkins](https://buythisglp.com/authors/wesley-jenkins)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20264 min readUpdated November 2026

Hit all three targets · tirzepatide · placebo at start · ≥5% weight + BP + lipids · 32–38% · 2–8% · ≥10% weight + BP + lipids · 28–37% · 1–5% · ≥15% weight + BP + lipids · 22–34% · 1–3% · Placebo column excludes the withdrawal group.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

Tirzepatide participants were more likely than placebo participants to meet a combined weight, blood pressure and cholesterol target in an exploratory analysis of four SURMOUNT trials. The analysis counted how often the same person reached all three thresholds [\[1\]](https://buythisglp.com/research/tirzepatide-three-targets-at-once#ref-1).

## Key takeaways

-   The composite required a weight-loss threshold, a systolic blood pressure decrease of at least 5 mmHg and non-HDL cholesterol below 130 mg/dL.
-   At the 15% weight-loss threshold, the paper reported 22–34% for tirzepatide and 1–3% for groups that started on placebo.
-   In SURMOUNT-4, participants who switched from tirzepatide to placebo after 36 weeks had a separate result. Eight percent met all three targets at the 15% weight-loss threshold.

## How the targets were measured

The [weight-loss tool](https://buythisglp.com/tools/glp1-expected-weight-loss) focuses on changes in body weight. This analysis also required a change in systolic blood pressure and a specific non-HDL cholesterol level. Researchers evaluated each trial separately at week 72 in SURMOUNT-1 through -3 and week 88 in SURMOUNT-4 [\[1\]](https://buythisglp.com/research/tirzepatide-three-targets-at-once#ref-1).

Eli Lilly funded the analysis. It used on-treatment data from participants with baseline and at least one follow-up measurement for each measure. The authors estimated missing endpoint measurements from available data. Treatment comparisons had P < .001 without adjustment for multiple comparisons[\[1\]](https://buythisglp.com/research/tirzepatide-three-targets-at-once#ref-1).

## How many participants reached all three

With a weight-loss threshold of at least 5%, the paper’s reported ranges were 32–38% with tirzepatide and 2–8% with placebo. At the 10% threshold the ranges were 28–37% and 1–5%, and at the 15% threshold they were 22–34% and 1–3%. The placebo ranges refer to groups that started on placebo [\[1\]](https://buythisglp.com/research/tirzepatide-three-targets-at-once#ref-1).

SURMOUNT-4 used a withdrawal design. Everyone received tirzepatide for 36 weeks before randomization to continue it or switch to placebo. Of those who switched, 14%, 10% and 8% met all three criteria using the 5%, 10% and 15% weight-loss thresholds, respectively [\[1\]](https://buythisglp.com/research/tirzepatide-three-targets-at-once#ref-1).

An improvement can fall short of the study threshold

Non-HDL cholesterol had to be below 130 mg/dL. For example, a decrease from 210 to 150 mg/dL would still leave someone above that threshold. Someone whose cholesterol was already below 130 mg/dL could meet the cholesterol criterion without a drop [\[1\]](https://buythisglp.com/research/tirzepatide-three-targets-at-once#ref-1).

## What the study tells us about heart outcomes

The guide to [tirzepatide’s cardiovascular evidence](https://buythisglp.com/research/is-tirzepatide-good-for-your-heart) covers trials that measured clinical events. The SURMOUNT analysis counted risk markers. In the separate SURPASS-CVOT trial of adults with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide for cardiovascular death, heart attack or stroke[\[2\]](https://buythisglp.com/research/tirzepatide-three-targets-at-once#ref-2).

## Frequently asked

What did the three-part target measure?

Participants needed to meet a weight-loss threshold, lower their systolic blood pressure by at least 5 mmHg, and finish with non-HDL cholesterol below 130 mg/dL.

Why is the SURMOUNT-4 placebo group different?

Those participants received tirzepatide for 36 weeks before switching to placebo, unlike groups assigned to placebo from the start.

Did this analysis measure heart attacks or strokes?

It measured weight, blood pressure and non-HDL cholesterol. Separate trials, including SURPASS-CVOT in adults with type 2 diabetes and atherosclerotic cardiovascular disease, measured actual cardiovascular events.

## Sources

1.  \[1\] Sattar N, et al. (2026). Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials PLOS ONE. [PMID 42594122](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0345032)
2.  \[2\] Nicholls SJ, et al. (2025). Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes New England Journal of Medicine. [Source](https://www.nejm.org/doi/full/10.1056/NEJMoa2505928)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
